Erasca, Inc. (NASDAQ:ERAS – Get Free Report) shares rose 5.4% during mid-day trading on Thursday. The company traded as high as $14.54 and last traded at $14.5070. Approximately 2,064,523 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 5,839,608 shares. The stock had previously closed at $13.76.
Erasca News Summary
Here’s some of the latest news about ERAS:
- Positive Sentiment: At the 32 mg daily dose, ERAS-0015 produced confirmed response rates of 44% in second-line-or-later pancreatic cancer patients with KRAS G12X mutations, 69% in the G12D/G12V pancreatic subgroup, and 60% in a small group of previously treated KRAS-mutant lung cancer patients. Erasca said the drug was generally well tolerated, with mostly low-grade side effects. Erasca Phase 1 data
- Neutral Sentiment: A Seeking Alpha contributor upgraded Erasca to “Buy,” citing ERAS-0015’s clinical progress and the company’s Bristol Myers Squibb collaboration. This is an individual analyst opinion, not a company announcement or a consensus rating. Seeking Alpha analysis
- Negative Sentiment: Despite the response rates, the findings are from an early-stage trial with small groups, so durability and results in larger studies remain uncertain. Coverage also highlighted unanswered questions around the data; investors may be weighing those risks against the promise. Erasca previously disclosed one fatal pneumonitis event related to ERAS-0015, despite the generally favorable safety profile reported in the update. Coverage of data questions
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on ERAS shares. Leerink Partners began coverage on Erasca in a research note on Tuesday. They set an “outperform” rating and a $35.00 price target on the stock. HC Wainwright upped their price objective on Erasca from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Bank of America raised their price objective on shares of Erasca from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, August 14th. Guggenheim lifted their target price on shares of Erasca from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Erasca in a report on Tuesday, September 8th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Erasca currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.17.
View Our Latest Analysis on ERAS
Erasca Price Performance
The company’s 50-day moving average price is $14.77 and its two-hundred day moving average price is $15.35. The company has a market capitalization of $4.78 billion, a price-to-earnings ratio of -13.75 and a beta of 0.68.
Erasca (NASDAQ:ERAS – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). On average, equities research analysts expect that Erasca, Inc. will post -0.52 EPS for the current fiscal year.
Institutional Investors Weigh In On Erasca
Several hedge funds and other institutional investors have recently modified their holdings of ERAS. BlackRock Inc. bought a new stake in Erasca in the 2nd quarter worth about $387,544,000. ARCH Venture Management LLC bought a new position in shares of Erasca in the second quarter valued at approximately $129,917,324. Janus Henderson Group PLC bought a new position in shares of Erasca in the first quarter valued at approximately $59,988,000. Assenagon Asset Management S.A. increased its position in shares of Erasca by 407.9% during the third quarter. Assenagon Asset Management S.A. now owns 4,128,332 shares of the company’s stock valued at $60,521,000 after acquiring an additional 3,315,456 shares during the last quarter. Finally, Commodore Capital LP purchased a new stake in shares of Erasca during the first quarter valued at approximately $51,372,000. Institutional investors own 67.78% of the company’s stock.
Erasca Company Profile
Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company’s pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.
Recommended Stories
- Five stocks we like better than Erasca
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.
